Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial

BMJ Open

Volumn 4, Issue 7, 2014, Pages

  Dakin, Helen A ^a   Wordsworth, Sarah ^a   Rogers, Chris A ^b   Abangma, Giselle ^c   Raftery, James ^d   Harding, Simon P ^e   Lotery, Andrew J ^f   Downes, Susan M ^g   Chakravarthy, Usha ^h   Reeves, Barnaby C ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c Swiss Re Services   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g OXFORD EYE HOSPITAL   (United Kingdom)

^h QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; COMPARATIVE STUDY; CONSULTATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; DRUG COST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PATIENT MONITORING; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RETINA MACULA AGE RELATED DEGENERATION; AGED; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; MACULAR DEGENERATION; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; STATISTICS AND NUMERICAL DATA; UNITED KINGDOM; VERY ELDERLY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; REGRESSION ANALYSIS; VISUAL ACUITY;

EID: 84904988058     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005094     Document Type: Article

References (37)

1. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.e5.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
3. British Medical Association. British National Formulary 62. London: Pharmaceutical Press, 2011. http://bnf.org/bnf/index.htm
4. Mitchell P. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Curr Med Res Opin 2011;27:1465-75.
5. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258-67.
6. Chakravarthy U, Harding SP, Rogers CA, et al; The IVAN Study Investigators. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411.
7. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
8. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
9. Mitchell P, Annemans L, White R, et al. Cost effectiveness of treatments for wet age-related macular degeneration. Pharmacoeconomics 2011;29:107-31.
10. Yanagi Y, Aihara Y, Fukuda T, et al. [Cost-effectiveness of ranibizumab, photodynamic therapy and pegaptanib sodium in the treatment of neovascular age-related macular degeneration in Japanese]. Nihon Ganka Gakkai Zasshi 2011;115:825-31.
11. Patel JJ, Mendes MA, Bounthavong M, et al. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model. J Eval Clin Pract 2012;18:247-55.
12. Gower EW, Cassard SD, Bass EB, et al. A cost-effectiveness analysis of three treatments for age-related macular degeneration. Retina 2010;30:212-21.
13. Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, et al. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2010;248:467-76.
14. Neubauer AS, Holz FG, Sauer S, et al. Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in Germany: model analysis from the perspective of Germany's statutory health insurance system. Clin Ther 2010;32:1343-56.
15. Smiddy WE. Economic implications of current age-related macular degeneration treatments. Ophthalmology 2009;116:481-7.
16. Stein JD, Newman-Casey PA, Mrinalini T, et al. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Ophthalmology 2014;121:936-45.
17. Fletcher EC, Lade RJ, Adewoyin T, et al. Computerized model of cost-utility analysis for treatment of age-related macular degeneration. Ophthalmology 2008;115:2192-8.
18. Raftery J, Clegg A, Jones J, et al. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007;91:1244-6. (Pubitemid 47344908)
19. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. Secondary Guide to the methods of technology appraisal 2013. 2013. http://www.nice.org.uk/media/D45/1E/ GuideToMethodsTechnologyAppraisal2013.pdf
20. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd edn. New York: Oxford University Press, 2005.
21. Dakin H, Wordsworth S. Cost-minimisation analysis versus cost-effectiveness analysis, revisited. Health Econ 2013;22:22-34.
22. Briggs AH, O'Brien BJ. The death of cost-minimization analysis? Health Econ 2001;10:179-84.
23. Jonsson B, Weinstein MC. Economic evaluation alongside multinational clinical trials. Study considerations for GUSTO IIb. Int J Technol Assess Health Care 1997;13:49-58. (Pubitemid 27138807)
24. Department of Health. PbR operational guidance and tariffs: 2011-12 tariff information spreadsheet. Secondary PbR operational guidance and tariffs: 2011-12 tariff information spreadsheet. 2011. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-124356
25. Department of Health. National Schedule of Reference Costs 2010-11 for NHS Trusts and PCTs combined. Secondary National Schedule of Reference Costs 2010-11 for NHS Trusts and PCTs combined. November 2011. http://www.dh.gov.uk/ prod-consum-dh/groups/dh-digitalassets/documents/digitalasset/dh-131148.xls
26. Curtis L. Unit Costs of Health and Social Care 2011. Pages 91, 129-150, 177-213.
27. Secondary Unit Costs of Health and Social Care 2011. Pages 91, 129-150, 177-213, 2011. http://www.pssru.ac.uk/archive/pdf/uc/uc2011/uc2011.pdf
28. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108. (Pubitemid 127453463)
29. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377-99.
30. Royston P. Multiple imputation of missing values: further update of ice, with an emphasis on interval censoring. Stata J 2007;7:445-64.
31. Hallstrom AP, Sullivan SD. On estimating costs for economic evaluation in failure time studies. Med Care 1998;36:433-6. (Pubitemid 128456386)
32. Gray A, Clarke P, Wolstenholme J, et al. Applied methods of cost-effectiveness analysis in health care. Oxford: Oxford University Press, 2011.
33. National Institute for Health and Clinical Excellence. Social value judgements: Principles for the development of NICE guidance. 2nd edn. Secondary Social value judgements: Principles for the development of NICE guidance. 2nd edn. 2008. http://www.nice.org.uk/media/C18/30/SVJ2PUBLICATION2008.pdf
34. National Institute for Health and Clinical Excellence. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration TA155: Costing template and report. Secondary Ranibizumab and pegaptanib for the treatment of age-related macular degeneration TA155: Costing template and report. August 2008. http://www.nice.org.uk/nicemedia/live/12057/41735/41735.xls
35. General Medical Council. Good practice in prescribing and managing medicines and devices. Secondary good practice in prescribing and managing medicines and devices. 2013. http://www.gmc-uk.org/static/documents/content/ Prescribing-guidance.pdf
36. Curtis LH, Hammill BG, Schulman KA, et al. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. [Erratum appears in Arch Ophthalmol 2010;128:1623]. Arch Ophthalmol 2010;128:1273-9.
37. Bayer Plc. Summary of product characteristics for Eylea 40 mg/mL solution for injection in a vial Secondary Summary of product characteristics for Eylea 40 mg/mL solution for injection in a vial. 2013. http://www.medicines.org.uk/ emc/medicine/27224/SPC/Eylea+40mg+ml+solution+for+injection+in+a+vial/